---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-026765"
form_type: "8-K"
ticker: "DNLI"
cik: "0001714899"
company_name: "Denali Therapeutics Inc."
filed_at: "2022-10-20T23:59:59+00:00"
generated_at: "2026-06-23T02:20:32.483905+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Denali Therapeutics prices $275M public offering of 10.4M shares at $26.50/share

## Summary
- Priced 10,377,359 shares of common stock at $26.50 per share for gross proceeds of ~$275M.
- Underwriters granted 30-day option to purchase up to an additional 1,556,603 shares.
- Gross proceeds would be ~$316.2M if option exercised in full.
- Offering expected to close on or about October 24, 2022, subject to closing conditions.
- Goldman Sachs, J.P. Morgan, and Jefferies are joint book-running managers.

## SEC filing metadata
- accession: 0001628280-22-026765
- form_type: 8-K
- ticker: DNLI
- cik: 0001714899
- company_name: Denali Therapeutics Inc.
- filed_at: 2022-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1714899/000162828022026765/0001628280-22-026765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1714899/000162828022026765/dnli-20221019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-026765
- JSON: https://secwatch.observer/filing/0001628280-22-026765.json
- Plain text: https://secwatch.observer/filing/0001628280-22-026765.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.